Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

730
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
730
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

790
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
790
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.5K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple authorship of scientific reports-two different evaluations are better than one.

Porto biomedical journal·2025
Same author

Isolated tricuspid valve regurgitation-avoid surgery, consider transcatheter intervention in patients with significant symptoms, treat atrial fibrillation.

Porto biomedical journal·2025
Same author

Renal, cardiac, and neurologic disease in a patient with Fabry disease, hemizygous for the c.639+5G>C intronic variant in the galactosidase alpha (<i>GLA</i>) gene.

Porto biomedical journal·2025
Same author

Medical therapeutics with an ecological concern.

Porto biomedical journal·2024
Same author

Age-Related Changes in Clinical and Analytical Variables in Chronic Hemodialyzed Patients.

International journal of molecular sciences·2024
Same author

Alkaline phosphatase and mortality in stroke patients: a systematic review.

Annals of translational medicine·2024

Related Experiment Video

Updated: Mar 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statins and the cholesterol mortality paradox.

José Pedro L Nunes1

  • 1Associate Professor, Department of Medicine, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Scottish Medical Journal
|November 28, 2016
PubMed
Summary

High-intensity LDL cholesterol lowering reduces cardiovascular events but not total mortality in secondary prevention, a phenomenon termed the LDL cholesterol mortality paradox. This suggests individualized treatment decisions are crucial.

Keywords:
LDL cholesterolLDL cholesterol mortality paradoxezetimibeguidelinesstatins

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Experiment Videos

Last Updated: Mar 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Statins significantly reduce cardiovascular events and mortality in secondary prevention compared to placebo.
  • Intensive LDL cholesterol lowering, using high-intensity statins or statin/ezetimibe, further reduces cardiovascular events but not total mortality.

Purpose of the Study:

  • To analyze the "LDL cholesterol mortality paradox" observed with intensive LDL-lowering therapies.
  • To evaluate the implications of this paradox for clinical decision-making in secondary cardiovascular prevention.

Main Methods:

  • Review of large-scale randomized controlled trials comparing placebo, low/standard-intensity, and high-intensity LDL cholesterol lowering therapies.
  • Analysis of cardiovascular events, total mortality, and adverse effects associated with different treatment intensities.

Main Results:

  • High-intensity LDL lowering significantly reduces cardiovascular events but shows no improvement in overall mortality.
  • Potential explanations for the paradox include prevention of non-fatal events or offsetting effects on mortality.
  • Adverse effects like diabetes mellitus and myopathy are associated with statin therapy.

Conclusions:

  • High-intensity LDL cholesterol lowering should be individualized in secondary prevention, considering patient preferences and overall health.
  • Current evidence does not support mandatory high-intensity LDL lowering due to the lack of impact on total mortality.
  • Further research is needed to determine if the LDL cholesterol mortality paradox applies to newer lipid-targeting drugs.